Glucagon‐like peptide‐1 receptor agonists and risk of acute pancreatitis in patients with type 2 diabetes |
| |
| Authors: | Heidi Storgaard MD PhD Frederik Cold MD Lise L. Gluud MD DMSc Tina Vilsbøll MD DMSc Filip K. Knop MD PhD |
| |
| Affiliation: | 1. Center for Diabetes Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark;2. Gastrounit, Hvidovre Hospital, University of Copenhagen, Hvidovre, Denmark;3. Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark;4. The Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark |
| |
| Abstract: | Glucagon‐like peptide‐1 receptor agonist (GLP‐1RAs) labels warn about acute pancreatitis (AP) and impose upon doctors the obligation to inform patients about symptoms of AP. Here we systematically reviewed the risk of AP in randomized placebo‐controlled trials (RCTs) investigating the effect of GLP‐1RAs in type 2 diabetes. We performed a systematic review with meta‐analysis of long‐term (minimum 24 months), placebo‐controlled GLP‐1RA RCTs in which AP was a predefined adverse event and adjudicated by blinded and independent adjudicating committees. Three high‐quality RCTs included a total of 9347 GLP‐1RA‐treated and 9353 placebo‐treated patients with type 2 diabetes. Compared to placebo, treatment with GLP1‐RA was not associated with increased risk of AP (Peto odds ratio 0.745 [95% CI, 0.47‐1.17]). Trial Sequential Analysis suggested that additional evidence is needed. In conclusion, this review found no evidence that treatment with GLP‐1RA increases the risk of AP in patients with type 2 diabetes. |
| |
| Keywords: | antidiabetic drug
GLP‐1 analogue incretin therapy liraglutide meta‐analysis type 2 diabetes |
|
|
